According to Data Bridge Market Research new Market report “North America Internal Neuromodulation Devices Market, By Product (Spinal Cord Stimulator (By Lead Type (Percutaneous, Paddle Lead)),, Deep Brain Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator, Gastric Nerve Stimulator), By Indication (Failed Back Surgery Syndrome, Parkinson’s disease, Urinary Incontinence, Epilepsy, Gastroparesis), By Battery Type (Primary, Rechargeable), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare), By Geography (U.S., Canada, Mexico) - Trends and Forecast to 2022”, has accounted value of USD 1.9 billion in 2015 and is expected to reach USD 4.7 billion by 2022, growing at a CAGR of 13.4%.
The North America Internal Neuromodulation devices market is driven by the rising incidence of orthopedic and muscoskeletal disorders such as failed back surgeries, and niche disease indications such as Alzheimer, Parkinson among others. The need of pain management and the inclusion of pain as the fifth vital factor have boosted the requirement of neuromodulation devices in this market. Also the market is experiencing a rising surge of technological advancements such as the new internal neuromodulation device from Enteromedics for the treatment of obesity related disorders. The market is expecting a exponential growth in the coming years owing to its clinical results. The internal neuromodulation markets growth is focused upon expansion of application of these devices.
The North America internal neuromodulation market is also technological driven; there are current innovations in lead materials and designs. For instance on 9th June 2015, WISE Srl, a privately held company developed new generation of implantable leads for Neuromodulation and Neuromonitoring. The electrodes are highly biocompatible, foldable, stretchable, minimally invasive and cheaper to produce than existing products and will overcome the major limitations of today’s technology. They will allow improving the treatment of patients that are already profiting from Neuromodulation, while at the same time expanding the use of Neuromodulation to fields and clinical indications in which the complex technical demands cannot be met by the current technology. On July 2, 2015, MESA International, MESA® 2 is K2M’s next-generation pedicle screw system. The system features a top-loading, low-profile screw that offers a dual-lead thread pattern for fast insertion. Companies such as Stimwave Technologies Incorporated, St. Jude Medical, and StimGuard LLC among others have started developing wireless conversions for the navigation of the therapy.
The North America internal neuromodulation devices market is segmented based on product type, battery type, indication type, end-user and geography.
On the basis of product the market is segmented into Spinal Cord Stimulator (SCS), Deep Brain Stimulator (DBS), Vagus Nerve Stimulator (VNS), Sacral Nerve Stimulator (SNS) and Gastric Nerve Stimulator (GNS). SCS dominates the North American market in 2015 and expected to grow at the highest CAGR in the forecast period, hence maintaining the dominance to 2022. The SCS devices are also classified based on lead type into paddle leads and percutaneous leads. The product segments are further divided into based on type of battery into rechargeable and primary battery type.
The internal neuromodulation devices have not been approved for many applications, so the indications for which this devices are used can be listed down. The market is further segmented based on indications of usage into failed back surgery syndrome, conditional regional pain syndrome, eschemia, Parkinson’s disease, Alzheimers, urinary incontinence, faecal incontinenece, epilepsy, gastroparesis and others.
On the basis of end-user (healthcare providers) the market is also segmented to give a understanding of the buying patterns and value supply chain of internal neuromodulation devices manufacturers and retailers. The end-users included in the scope of this report are hospitals, clinics, home healthcare, and community healthcare
Based on geography the North America internal neuromodulation devices market is segmented into 3 countries U.S. Canada and Mexico. U.S. is the dominant market with 92.1% market share in 2015, and is expected to grow at the highest CAGR of 13.9% in the forecast years.
The North America internal neuromodulation devices market is highly competitive and the major players have used various strategies such as new product launches, expansions, agreements, joint ventures, partnerships, acquisitions, and others to increase their footprints in this market. Some examples of recent strategies/developments are: St. Jude Medical received FDA approval for Axium its neurostimulation device for dorsal roost ganglion used to treat patients with chronic intractable pain. The report includes market shares of internal neuromodulation devices for North America, U.S., Canada and Mexico.
The North America internal neuromodulation devices market report contains an in-depth profiling of the key market players, along with the recent developments (New product launches, partnerships, agreements, collaborations, and joint ventures) and strategies adopted by them to sustain and strengthen their positions in the market. Some of the major players operating in this market are Medtronic, Boston Scientific Corporation, St. Jude Medical, Inc., Nevro Corporation, Cyberonics, Inc. among other companies. The emerging entrant companies in the U.S. internal neuromodulation market are Neuros Medical, Inc., Inspire Medical Systems Inc., StimGuard LLC, SPR Therapeutics LLC, Neuros Medical Inc.
Browse Related Reports:
Global Internal Neuromodulation Devices Market, By Product (Spinal Cord Stimulator (By Lead Type (Percutaneous, Paddle Lead)),, Deep Brain Stimulator, Vagus Nerve Stimulator, Sacral Nerve Stimulator, Gastric Nerve Stimulator), By Indication (Failed Back Surgery Syndrome, Parkinson’s disease, Urinary Incontinence, Epilepsy, Gastroparesis), By Battery Type (Primary, Rechargeable), By End-User (Hospitals, Clinics, Home Healthcare, Community Healthcare), By Geography (North America, Europe, Asia-Pacific, Middle East and Africa, South America, Rest of the World) - Trends and Forecast to 2022
Europe Interventional Neurology Devices Market, By Product (Aneurysm Coiling and Embolization Devices (Embolic Coils, Flow Diversion Devices, Liquid Embolic Devices), Angioplasty Devices (Carotid Artery Stents, Embolic Protection Systems), Micro Support Devices (Microguidewires, Microcatheters), Neurothrombectomy Devices (CLOT Retrieval Devices, Suction and Aspiration Devices, Snares)), By Procedure (Embolization, Angioplasty, Neurothrombectomy, Others), By End-User (Hospitals, Neurology Clinics, Ambulatory Care Centers, Others), By Country (Germany, France, U.K., Spain, Italy, Russia, Netherlands, Turkey, Belgium, Switzerland, Rest of Europe) – Trends and Forecast to 2022
4th Floor, Mega Center,
Magarpatta City, Pune – 411028
Visit Data Bridge Blog@ http://databridgemarketresearch.com/blog/
U.S. Internal Neuromodulation Devices Market - Industry Trends and Forecast to 2024
Global Internal Neuromodulation Devices Market – Industry Trends - Forecast to 2026
North America Internal Neuromodulation Devices Market - Trends and Forecast to 2024
Europe Internal Neuromodulation Devices Market - Trends and Forecast to 2024
Asia Pacific (APAC) Internal Neuromodulation Devices Market -Trends and Forecast to 2024
Data Bridge Market Research has added a new market report on “Global Internal Neuromodulation Devices Market – Analysis and Forecast 2013 – 2020” to their product portfolio of healthcare reports.
Internal Neuromodulation Devices Market is Driven by Increasing Number of Brain Disease Patients
Global Internal Neuromodulation Devices Market poised to reach USD 12.18 billion by 2024
Europe Internal Neuromodulation Devices Market poised to grow at 12.9% till 2022
APAC Internal Neuromodulation Devices Market poised to grow at 20.1%
Global Internal Neuromodulation Devices Market is Growing at a Significant Rate in the Forecast Period 2018-2025